Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deffered Revenue (2016)

Rein Therapeutics (RNTX) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $11000.0 as the latest value for Q4 2016.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $11000.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $11000.0, a N/A change, with the full-year FY2016 number at $11000.0, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $11000.0 for Q4 2016 at Rein Therapeutics.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $11000.0 in Q4 2016 to a low of $11000.0 in Q4 2016.